{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:03:00Z","timestamp":1773075780833,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"crossref","award":["No. 2023YFS0103"],"award-info":[{"award-number":["No. 2023YFS0103"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["No.320.6750.2022-19-23"],"award-info":[{"award-number":["No.320.6750.2022-19-23"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13571-9","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:36:56Z","timestamp":1737988616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihui","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"3","key":"13571_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"13571_CR2","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","volume":"22","author":"L Biganzoli","year":"2021","unstructured":"Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of breast Cancer specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22(7):e327\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30741-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13571_CR3","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/S2666-7568(21)00280-4","volume":"3","author":"N Carleton","year":"2022","unstructured":"Carleton N, Nasrazadani A, Gade K, et al. Personalizing therapy for early-stage estrogen receptor-positive breast cancer in older women. Lancet Healthy Longev. 2022;3(1):e54\u201366. https:\/\/doi.org\/10.1016\/S2666-7568(21)00280-4.","journal-title":"Lancet Healthy Longev"},{"key":"13571_CR4","doi-asserted-by":"publisher","unstructured":"Denlinger CS, Koh W. The NCCN 2024 Annual Conference. J Natl Compr Canc Netw. 2024;22(Supplement):e245001. https:\/\/doi.org\/10.6004\/jnccn.2024.5001.","DOI":"10.6004\/jnccn.2024.5001"},{"issue":"8","key":"13571_CR5","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1245\/s10434-014-3775-6","volume":"21","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Caudle AS, Yang W, et al. Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: is there a Way Forward for Sentinel Lymph Node Dissection in clinically node-positive breast Cancer patients treated with Neoadjuvant Chemotherapy? Ann Surg Oncol. 2014;21(8):2468\u201373. https:\/\/doi.org\/10.1245\/s10434-014-3775-6.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"13571_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast Cancer with Cytologically confirmed Axillary Lymph Node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2(4):508\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4935.","journal-title":"JAMA Oncol"},{"issue":"36","key":"13571_CR7","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304\u201311. https:\/\/doi.org\/10.1200\/JCO.2005.02.5023.","journal-title":"J Clin Oncol"},{"issue":"11","key":"13571_CR8","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-016-5277-1","volume":"23","author":"J Vila","year":"2016","unstructured":"Vila J, Mittendorf EA, Farante G, et al. Nomograms for Predicting Axillary response to Neoadjuvant Chemotherapy in clinically node-positive patients with breast Cancer. Ann Surg Oncol. 2016;23(11):3501\u20139. https:\/\/doi.org\/10.1245\/s10434-016-5277-1.","journal-title":"Ann Surg Oncol"},{"key":"13571_CR9","doi-asserted-by":"publisher","unstructured":"Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998;83(7):1362\u20138. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19981001)83:7%3C1362::aid-cncr13%3E3.0.co;2-2.","DOI":"10.1002\/(sici)1097-0142(19981001)83:7%3C1362::aid-cncr13%3E3.0.co;2-2"},{"issue":"24","key":"13571_CR10","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657\u201363. https:\/\/doi.org\/10.1200\/JCO.2006.07.4062.","journal-title":"J Clin Oncol"},{"issue":"7","key":"13571_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol"},{"issue":"14","key":"13571_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA"},{"issue":"3","key":"13571_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol"},{"issue":"12","key":"13571_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO\/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346\u201366. https:\/\/doi.org\/10.1200\/JCO.19.02309.","journal-title":"J Clin Oncol"},{"issue":"22","key":"13571_CR15","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"issue":"3A","key":"13571_CR16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2559.2002.14691.x","volume":"41","author":"CW Elston","year":"2002","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 2002;41(3A):154\u201361.","journal-title":"Histopathology"},{"issue":"1","key":"13571_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.32074\/1591-951X-1-20","volume":"112","author":"G Cserni","year":"2020","unstructured":"Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112(1):25\u201341. https:\/\/doi.org\/10.32074\/1591-951X-1-20.","journal-title":"Pathologica"},{"issue":"9","key":"13571_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, Bossuyt V, Viale G, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28(9):1185\u2013201. https:\/\/doi.org\/10.1038\/modpathol.2015.74.","journal-title":"Mod Pathol"},{"key":"13571_CR19","doi-asserted-by":"publisher","unstructured":"Spring L, Greenup R, Niemierko A, et al. Pathologic complete response after Neoadjuvant Chemotherapy and Long-Term outcomes among Young Women with breast Cancer [J]. J Natl Compr Canc Netw. 2017;15(10):1216\u201323. https:\/\/doi.org\/10.6004\/JNCCN.2017.0158.","DOI":"10.6004\/JNCCN.2017.0158"},{"issue":"9938","key":"13571_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019;393(10175):986. Doi: 10.1016\/S0140-6736(18)32772-7]. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"issue":"13","key":"13571_CR21","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1245\/s10344-022-12206-8","volume":"29","author":"AD Williams","year":"2022","unstructured":"Williams AD, Dang CT, Sevilimedu V, Morrow M, Barrio AV. Neoadjuvant chemotherapy for breast Cancer in the Elderly: are we accomplishing our treatment goals? Ann Surg Oncol. 2022;29(13):8002\u201311. https:\/\/doi.org\/10.1245\/s10344-022-12206-8.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"13571_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of Sentinel Lymph Node surgery in patients presenting with node-positive breast Cancer (T0-T4, N1-N2) who receive Neoadjuvant Chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000001375.","journal-title":"Ann Surg"},{"issue":"3","key":"13571_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF02984541","volume":"11","author":"D Krag","year":"2004","unstructured":"Krag D, Harlow S, Julian T. Breast cancer and the NSABP-B32 sentinel node trial. Breast Cancer. 2004;11(3):221\u201366. https:\/\/doi.org\/10.1007\/BF02984541.","journal-title":"Breast Cancer"},{"issue":"13","key":"13571_CR24","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1245\/s10434-021-10195-8","volume":"28","author":"SP Myers","year":"2021","unstructured":"Myers SP, Ahrendt GM, Lee JS, et al. Association of Tumor Molecular Subtype and Stage with breast and axillary pathologic complete response after neoadjuvant chemotherapy for breast Cancer. Ann Surg Oncol. 2021;28(13):8636\u201342. https:\/\/doi.org\/10.1245\/s10434-021-10195-8.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"13571_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-019-05214-y","volume":"176","author":"HJ Choi","year":"2019","unstructured":"Choi HJ, Ryu JM, Kim I, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2019;176(3):591\u20136. https:\/\/doi.org\/10.1007\/s10549-019-05214-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"13571_CR26","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","volume":"28","author":"A Weiss","year":"2021","unstructured":"Weiss A, Campbell J, Ballman KV, et al. Factors Associated with nodal pathologic complete response among breast Cancer patients treated with Neoadjuvant Chemotherapy: results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Ann Surg Oncol. 2021;28(11):5960\u201371. https:\/\/doi.org\/10.1245\/s10434-021-09897-w.","journal-title":"Ann Surg Oncol"},{"issue":"27","key":"13571_CR27","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the Axilla in early-stage breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39(27):3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"J Clin Oncol"},{"issue":"11","key":"13571_CR28","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs no axillary surgery in patients with small breast Cancer and negative results on Ultrasonography of Axillary Lymph nodes: the SOUND Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1557\u201364. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3759.","journal-title":"JAMA Oncol"},{"issue":"12","key":"13571_CR29","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.25152","volume":"116","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884\u20139. https:\/\/doi.org\/10.1002\/cncr.25152.","journal-title":"Cancer"},{"issue":"1","key":"13571_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00000658-199907000-00011","volume":"230","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1):72\u20138. https:\/\/doi.org\/10.1097\/00000658-199907000-00011.","journal-title":"Ann Surg"},{"issue":"8","key":"13571_CR31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/ijc.33726","volume":"149","author":"C Cha","year":"2021","unstructured":"Cha C, Ahn SG, Kim D, et al. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Int J Cancer. 2021;149(8):1585\u201392. https:\/\/doi.org\/10.1002\/ijc.33726.","journal-title":"Int J Cancer"},{"issue":"6","key":"13571_CR32","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.089","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, et al. Axillary Pathologic Complete Response after Neoadjuvant systemic therapy by breast Cancer subtype in patients with initially, clinically node-positive disease: a systematic review and Meta-analysis. JAMA Surg. 2021;156(6):e210891. https:\/\/doi.org\/10.1001\/jamasurg.2021.089.","journal-title":"JAMA Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13571-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:36:58Z","timestamp":1737988618000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13571-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13571"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13571-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Medical Research and Medical New Technology of Sichuan Cancer Hospital(Number: SCCHEC-02-2023-030).The procedures used are consistent with the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}